PartnershipApr 4, 2026, 07:40 AM
Denali Therapeutics Receives Notice of Termination from Takeda for DNL593 Collaboration Agreement
AI Summary
Denali Therapeutics received written notice from Takeda Pharmaceutical Company Limited regarding its decision to terminate the Collaboration Agreement for DNL593 (PTV:PGRN), a program for co-development and co-commercialization. The termination, driven by strategic considerations and not related to efficacy or safety data, will become effective in 60 days, reverting all rights in the DNL593 program to Denali and eliminating further financial obligations to Takeda.
Key Highlights
- Takeda terminates Collaboration Agreement with Denali for DNL593.
- Termination is due to strategic considerations, not efficacy or safety concerns.
- All rights to the DNL593 program will revert to Denali in 60 days.
- Denali will have no further financial obligations to Takeda following termination.